Takeda and Protagonist Therapeutics received FDA approval for rusfertide, branded as Mimrylo, to treat polycythemia vera, a rare blood disorder. The approval places a new option in the PV treatment landscape, targeting patients with persistent disease burden despite existing therapies. The decision underscores continued FDA engagement in rare hematologic indications and expands the set of reimbursable pathways for managing PV-related outcomes. For developers, Mimrylo’s approval also highlights the importance of demonstrating clinically meaningful benefit in genetically or physiologically defined patient groups. Market and pipeline implications are likely to be felt most by companies targeting erythrocytosis control and downstream thrombosis risk reduction in PV.